Description: If you are wondering whether IQVIA Holdings is fairly priced or if there is still room for value, this article walks you through what the current share price might be implying. The stock last closed at US$241.57, with returns of 0.4% over 7 days, 8.7% over 30 days, 7.2% year to date and 22.0% over the past year, which may have shifted how the market sees its risk and opportunity. Recent attention on IQVIA has centered on its role as a large player in contract research and real world data...

Description: Here’s what you need to know before life sciences analytics company IQVIA reports its Q4 earnings.

Description: Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Description: The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up...

Description: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Description: IQVIA Holdings shares jump 25.5% in three months as AWS partnership, growing R&DS backlog and buybacks lift its earnings outlook.

Description: Let's talk about the popular IQVIA Holdings Inc. ( NYSE:IQV ). The company's shares saw a significant share price rise...

Description: Key Insights The projected fair value for IQVIA Holdings is US$309 based on 2 Stage Free Cash Flow to Equity IQVIA...

Description: Tempus AI rallies in 2025, but a Hold rank and mixed style scores argue for patience until pricing, FDA, and MRD milestones firm up.

Description: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Description: John Wiley & Sons, Inc. (NYSE:WLY) is one of the best dividend stocks to buy. On November 25, WLY disclosed that it has entered a partnership with IQVIA Holdings Inc. (NYSE:IQV) to provide a trusted solution to enforce the Clinical Outcome Assessment (COA) execution. Through this partnership, COA instruments are easily available to pharmaceutical and […]

Description: If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...

Description: Biotech stocks and research shares diverged Thursday after reports suggested the FDA will soon require just one pivotal study.

Description: RESEARCH TRIANGLE PARK, N.C., December 02, 2025--IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic collaboration with Amazon Web Services (AWS), naming AWS as IQVIA’s Preferred Agentic Cloud Provider. The partnership, revealed at AWS re:Invent, is a major step in the digital transformation of healthcare and life sciences, aiming to revolutionize cl

Description: Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

Description: Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Let's talk about the popular IQVIA Holdings Inc. ( NYSE:IQV ). The company's shares received a lot of attention from a...

Description: Key Insights IQVIA Holdings' estimated fair value is US$309 based on 2 Stage Free Cash Flow to Equity Current share...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: IQVIA Holdings (IQV) just delivered third-quarter earnings and revenue that came in above expectations, providing investors with a bit more optimism around the company’s full-year forecast. This earnings update has sparked fresh discussions about the company’s outlook. See our latest analysis for IQVIA Holdings. Momentum around IQVIA Holdings has been building, with shares gaining 13.14% over the past three months as investors responded positively to its earnings beat and upbeat outlook. The...

Description: IQVIA Holdings has recently seen its consensus analyst price target rise significantly, climbing from $223.42 to $246.84. This upward revision reflects increased analyst confidence, due to the company’s workforce stability, competitive business-to-business performance, and strategic diversification across technology and analytics. Stay tuned to discover how you can monitor the evolving outlook and stay ahead of key narrative shifts for IQVIA Holdings. Analyst Price Targets don't always...

Description: Green Dot's Q3 results are on deck, with strong B2B momentum expected, but earnings forecasts suggest a potential quarterly loss.

Description: MOGO is set to post third-quarter 2025 results, with revenues expected to dip y/y. However, its growing crypto strategy can boost long-term potential.

Description: RESEARCH TRIANGLE PARK, N.C., November 05, 2025--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.

Description: IQVIA's third quarter results reflected stable operational execution, with revenue and profit slightly ahead of Wall Street expectations. Management identified robust free cash flow generation and a healthy pipeline of clinical trial bookings as primary contributors to the quarter’s performance. CEO Ari Bousbib emphasized improvements in industry demand, noting that net bookings in the clinical segment grew 13% year over year, while the company’s backlog reached $32.4 billion. Bousbib credited d

Description: Shares of clinical research company IQVIA (NYSE: IQV) fell 2.5% in the afternoon session after TD Cowen downgraded its rating on the stock from Buy to Hold. The firm cited valuation concerns as the main reason for the change, noting that IQVIA's current stock price already reflected its growth outlook. Analysts also pointed to "generally subdued market conditions and margin pressures" as factors that limited the potential for further gains. While TD Cowen did raise its price target on the shares

Description: Boeing upgraded, Charter downgraded: Wall Street's top analyst calls

Description: Last week saw the newest third-quarter earnings release from IQVIA Holdings Inc. ( NYSE:IQV ), an important milestone...

Description: IQVIA Holdings Inc (IQV) reports highest-ever quarterly free cash flow and a robust backlog, despite modest EBITDA growth and high leverage.

Description: IQVIA Holdings (IQV) delivered earnings growth averaging 20.1% per year over the past five years, but the most recent year saw net profit margins slip to 8.1% from 9.2% a year ago. Looking ahead, analysts forecast annual earnings growth of 13.99% and revenue gains of 5.3% per year, both trailing broader US market expectations. While valuation multiples appear attractive and ongoing profit or revenue growth continue to be clear rewards for investors, the company's declining profit margins and...

Description: Clinical research company IQVIA (NYSE: IQV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.2% year on year to $4.1 billion. The company expects the full year’s revenue to be around $16.2 billion, close to analysts’ estimates. Its non-GAAP profit of $3 per share was 0.8% above analysts’ consensus estimates.

Description: While the top- and bottom-line numbers for IQVIA (IQV) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: IQV posts stronger-than-expected third-quarter 2025 earnings and revenue gains. It lifts the full-year guidance as all key segments show growth momentum.

Description: IQVIA (IQV) delivered earnings and revenue surprises of +1.35% and +0.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 5.2% year on year to $4.1 billion. The company expects the full year’s revenue to be around $16.2 billion, close to analysts’ estimates. Its non-GAAP profit of $3 per share was 0.8% above analysts’ consensus estimates.

Description: The Durham, North Carolina-based company said it had net income of $1.93 per share. Earnings, adjusted for one-time gains and costs, came to $3 per share. The results surpassed Wall Street expectations.

Description: RESEARCH TRIANGLE PARK, N.C., October 28, 2025--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2025.

Description: Clinical research company IQVIA (NYSE: IQV) will be reporting earnings this Tuesday morning. Here’s what investors should know.

Description: Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 13.5% return has trailed the S&P 500 by 9.4 percentage points.

Description: IQV readies its Q3 report, with revenues and EPS expected to rise on biopharma strength and cost control despite muted beat odds.

Description: IQVIA Holdings has seen its consensus analyst price target rise slightly to $223 from $218, reflecting a modest uptick in projected fair value. Analysts link this change to confidence in the company's improving operational stability, reduced client risk exposure, and its diversified technology and analytics offerings. At the same time, industry headwinds remain in focus. Stay tuned for insights on how to monitor shifts in the evolving IQVIA narrative as market expectations continue to...

Description: TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: RESEARCH TRIANGLE PARK, N.C., October 21, 2025--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 12:30 p.m. ET.

Description: IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Shares of clinical research company IQVIA (NYSE: IQV) jumped 3.6% in the afternoon session after Bank of America raised its price target on the company's shares to $230 from $215. The adjustment from the investment bank suggested a more positive outlook on the stock's potential value. This move occurred while the company maintained an average rating of 'buy' among analysts polled by FactSet. An increased price target can signal confidence in a company's future performance, which often attracts i